Actavis divests its stake in PLIVA

24-Oct-2006

Actavis Group announced that a total of 20.8% of PLIVA's share capital that Actavis controls through a combination of share ownership and options to acquire shares has been tendered into Barr's offer to acquire all outstanding shares in PLIVA at HRK820 per share.

The shareholding was a strategic stake acquired by Actavis to support its proposed bid for PLIVA. Following Actavis' Board's decision not to increase its offer above the price of HRK820 per share being offered by Barr Pharmaceuticals for PLIVA, Actavis has withdrawn its proposal and no longer sees the benefits of retaining its shareholding in PLIVA.

Other news from the department business & finance

Most read news

More news from our other portals

Discover the latest developments in battery technology!